Drug Discovery

FDA approves Acadia’s Daybue Stix for Rett syndrome

The US Food and Drug Administration has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a dye and preservative-free powder formulation of trofinetide, for oral solution, to treat Rett syndrome.

Sobi buys Arthrosi to expand gout treatment pipeline

Swedish Orphan Biovitrum (Sobi) has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics, a move that will expand Sobi’s presence in the gout treatment market.

Boehringer’s Jascayd gains China’s NMPA approval for PPF

China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis (PPF).

Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals.

China’s NMPA approves Sanofi’s rare haematologic disease treatments

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease treatments, Qfitlia (fitusiran) and Cablivi (caplacizumab), for patients with haemophilia and acquired thrombotic thrombocytopenic purpura (aTTP) respectively.

Formycon and Zydus sign exclusive agreement for FYB206 supply

Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab), in Canada and the US.

Inductive Bio gains $21m ARPA-H funds for drug prediction models

New York City-based tech company Inductive Bio has secured up to $21m from the US Advanced Research Projects Agency for Health (ARPA-H) to lead the development of AI drug toxicity prediction models, aimed at improving drug safety assessment and minimising reliance on animal testing.

Agilent and Monash University Malaysia to set up biodiscovery hub

Agilent Technologies has expanded its collaboration with Monash University Malaysia (MUM) for the establishment of the MUM Proteomics & Metabolomics Platform (MUMPMP)-Agilent BioDiscovery Hub.

FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL

Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for the expanded use of Jaypirca (pirtobrutinib) tablets, in 100mg and 50mg doses, to treat adults with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).